Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Dysfunction of cell bioenergetics is a common feature of neurodegenerative diseases, the
most common of which is Alzheimer's disease (AD). Disrupted energy utilization implicates …

Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that
tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (A β). We …

Given the acknowledged lack of success in Alzheimer's disease (AD) drug development
over the past two decades, the objective of this review was to derive key insights from the …

Alzheimer disease (AD) is a progressive and deleterious neurodegenerative disorder that
affects mostly the elderly population. At the moment, no effective treatments are available in …

Vascular contributions to cognitive impairment and dementia (VCID) are characterized by
the aging neurovascular unit being confronted with and failing to cope with biological insults …

The incidence of stroke and dementia are diverging across the world, rising for those in low-
and middle-income countries and falling in those in high-income countries. This suggests …

Alzheimer's disease is the most common form of dementia, and the prodromal phases of
Alzheimer's disease can last for decades. Vascular dementia is the second most common …

Cerebrovascular disease underpins vascular dementia (VaD), but structural and functional
changes to the cerebral vasculature contribute to disease pathology and cognitive decline in …

The development of advanced neuroimaging techniques and their deployment in large
cohorts has enabled an assessment of functional and structural brain network architecture at …